Latest pharma updates on Gastric Cancer
FDA Approves Durvalumab (Imfinzi) + FLOT Regimen for Resectable Gastric & GEJ Cancer
The U.S. FDA has given the green light to AstraZeneca’s durvalumab (Imfinzi) in combination with the FLOT chemothe...
Read Full Story